• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model

    12/18/24 8:30:00 AM ET
    $CHRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CHRO alert in real time by email

    FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it achieved its endpoints in two pre-clinical in vivo models of the Company's nerve block formulations for acute pain, showing material improvement over the existing standard of care, bupivacaine, in both efficacy and duration.

    "We are very pleased with the results, which potentially demonstrate that nerve blocks with our NaV1.7 inhibitors may be viable options for the treatment of acute and postoperative pain," stated Dr. Eric Lang, Chief Medical Officer of Channel. "Additionally, we believe this drug has the potential to improve on existing postoperative therapeutic options while opening the door for success with our other programs," concluded Dr. Lang.

    About the trial

    The Company performed a thermal hyperalgesia test in rodents with a placebo arm, bupivacaine arm and four arms of the main formulations of the Company's molecule. The Company also performed a mechanical allodynia test in rodents with the same arms as above. For both models, the drugs were administered as a sciatic nerve block. All four Company formulations showed a depot effect in excess of four days, an improvement over bupivacaine, the current standard of care.

    Results

    The results of the thermal hyperalgesia results are shown in the chart below. After thirty minutes, three of the four formulations showed materially better efficacy than bupivacaine, with each of the three being statistically superior to placebo for more than two days longer than bupivacaine. One of the formulations remained statistically superior to placebo for more than four days. Further, as NaV1.7 does not have an impact on mobility, this approach may offer a better option for post-surgical physical therapy as current nerve block therapies cause temporary paralysis in the affected area.

    Chart 1

    Similarly for the mechanical allodynia test results, three of the four formulations showed statistically better efficacy for a longer duration of time than bupivacaine. The mechanical allodynia test is shorter in duration, reflecting the subject's innate swift recovery rate to surgical incisions. Nonetheless, the results mirrored the successful results set forth with the thermal hyperalgesia test.

    Chart 2

    "These results support our belief that NaV1.7 is a potent and effective target for the development of drugs for the treatment of pain," stated Frank Knuettel II, Chief Executive Officer of Channel. "With these results, investors should feel encouraged that we have a strong development path towards successfully launching drugs with considerable market opportunities," Mr. Knuettel concluded.

    According to BioSpace, the post-operative global pain market was valued at $2.6 billion in 2023, of which, Exparel, a bupivacaine liposome injectable suspension, generated approximately $538 million in revenue. It is this existing market that the Company is tackling, as well as the post-surgical opioid market opportunity, as these results show potential efficacy for a long period of time, which should reduce post-surgical opioid usage.

    Results are expected for the studies conducted on the Company's eye drops for the treatment of various types of eye pain – including severe dry eye, corneal abrasions, surgical intervention and other indications – in late January 2025.

    About Channel

    Channel Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The Company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain and post-surgical nerve blocks. For company updates and to learn more about Channel, visit www.channeltherapeutics.com or follow us on social media.

    Forward-Looking Statements

    This press release contains forward-looking statements regarding the Company's current expectations. These forward-looking statements include, without limitation, references to the Company's expectations regarding (i) the Company's belief that nerve blocks with its NaV1.7 inhibitors may be viable options for the treatment of acute and postoperative pain, (ii) the Company's belief the Company's NaV1.7 inhibitor has the potential to improve on existing postoperative therapeutic options while opening the door for success with the Company's other programs, (iii) the Company's belief that the NaV1.7 inhibitor may offer a better option for post-surgical physical therapy as compared to bupivacaine, (iv) the Company's belief that investors should feel encouraged that the Company has a strong development path towards successfully launching drugs with considerable market opportunities, and (iv) the timing of expected results on the Company's eye drops for the treatment of various types of eye pain. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to there being no guarantee that the trading price of the Company's Common Stock will be indicative of the Company's value or that the Company's Common Stock will become an attractive investment in the future. These and other risks and uncertainties are described more fully in in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law.

    Channel Media and Investor Inquires:

    For Investor Inquiries:

    Mike Moyer

    Managing Director, LifeSci Advisors, LLC

    [email protected]



    Primary Logo

    Get the next $CHRO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CHRO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CHRO
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Channel Therapeutics Corporation

      SCHEDULE 13D/A - Pelthos Therapeutics Inc. (0001919246) (Subject)

      7/3/25 9:07:22 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13D filed by Channel Therapeutics Corporation

      SCHEDULE 13D - Pelthos Therapeutics Inc. (0001919246) (Subject)

      7/3/25 4:05:07 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Channel Therapeutics Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - Pelthos Therapeutics Inc. (0001919246) (Filer)

      7/2/25 5:22:26 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Malamut Richard bought $9,825 worth of shares (10,400 units at $0.94) (SEC Form 4)

      4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

      9/16/24 4:56:55 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO, Pres., CFO, Treas & Secty Francis Knuettel Ii bought $5,044 worth of shares (5,200 units at $0.97) (SEC Form 4)

      4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

      9/16/24 4:55:23 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO, Pres., CFO, Treas & Secty Francis Knuettel Ii bought $10,955 worth of shares (12,000 units at $0.91) (SEC Form 4)

      4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

      9/12/24 5:35:41 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Chromocell Therapeutics Corporation

      SC 13G/A - Chromocell Therapeutics Corp (0001919246) (Subject)

      11/13/24 4:05:24 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Chromocell Therapeutics Corporation

      SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)

      3/4/24 4:07:02 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Chromocell Therapeutics Corporation

      SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)

      3/1/24 5:19:37 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

      The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name "Pelthos Therapeutics Inc." and will trade on the NYSE American exchange under the ticker symbol "PTHS" starting on July 2, 2025 DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the previously announced merger agreement pursuant to which CHRO Me

      7/2/25 7:00:00 AM ET
      $CHRO
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement

      FREEHOLD, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), an emerging leader in the development of non-opioid pain treatment therapeutics, today announced a 10-for-one reverse split (the "Reverse Stock Split") of the Company's common stock (the "Common Stock"). The Reverse Stock Split is intended to increase the market price per share of the Company's Common Stock and help the Company satisfy the initial listing requirements of the NYSE American (the "NYSE American") in connection with the anticipated closing of the previously announced merger of CHRO Merger Sub, Inc., a wholly owned subsidiary of the Company, with and in

      6/27/25 9:15:00 AM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Channel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using its NaV1.7 Inhibitor in Multiple Preclinical In Vivo Models

      FREEHOLD, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has achieved its predefined endpoints in two pre-clinical animal models of the Company's eye drop formulations ("CT2000") for the treatment of both acute ocular pain as well as chronic ocular surface pain commonly associated with dry eye disease. "We are very pleased with the results of these animal efficacy studies, which adds to the Depot formulation study results announced in December 2024, demonstrating a viable path forward in treating both post-surgical pain and ch

      5/14/25 8:00:00 AM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Friedberg Ezra M converted options into 80,000 shares (SEC Form 4)

      4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

      7/3/25 9:05:54 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Francis Knuettel Ii converted options into 10,000 shares (SEC Form 4)

      4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

      7/3/25 9:04:18 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Davis Todd C converted options into 1,500,000 shares (SEC Form 4)

      4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

      7/3/25 9:02:33 PM ET
      $CHRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

      The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name "Pelthos Therapeutics Inc." and will trade on the NYSE American exchange under the ticker symbol "PTHS" starting on July 2, 2025 DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the previously announced merger agreement pursuant to which CHRO Me

      7/2/25 7:00:00 AM ET
      $CHRO
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations